Zolmitriptan: Differences from Sumatriptan

References

• Menken M, Munsat TL, Toole JF. The global burden of disease study – implications for neurology. Arch. Neurol. 2000;57:418–20
   PubMed Web of Science ®Google Scholar
• Lance JW, Goadsby PJ. Mechanism and Management of Headache, 6th edn. London: Butterworth-Heinemann, 1998
   Google Scholar
• Davies GM, Santanello NC, Lipton RB. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000;20:554–60
   PubMed Web of Science ®Google Scholar
• Ferrari MD. Migraine. Lancet 1998;351:1043–51
   PubMed Web of Science ®Google Scholar
• Martin GR. Preclinical profile of the novel 5-HT1D receptor agonist 311C90. In: Rose FC, ed. New Advances in Headache Research. London: Smith-Gordon, 1994:3–4. vol 4
   Google Scholar
• Goadsby PJ, Peatfield R. Zolmitriptan in the acute treatment of migraine: an overview. Rev Contemp Pharmacother 2000;11:91–7
   Google Scholar
• Goadsby PJ. 5-HT1B/1D agonists in migraine: comparative pharmacology and its therapeutic implications. CNS Drugs 1998;10:271–86
   Web of Science ®Google Scholar
• Goadsby PJ. A Triptan too far. J Neurol Neurosurg Psychiatry 1998;64:143–7
   PubMed Web of Science ®Google Scholar
• Weitzel KW, Thomas ML, Small RE, Goode JVR. Migraine: a comprehensive review of new treatment options. Pharmacotherapy 1999;19:957–73
   PubMed Web of Science ®Google Scholar
• Hill AP, Hyde RM, Robertson AD, et al. Oral delivery of 5-HT1D receptor agonists: towards the discovery of 311C90, a novel antimigraine agent. Headache 1995;34: 308
   Google Scholar
• Martin GR. Pre-clinical pharmacology of zolmitriptan (ZomigTM; formerly 311C90), a centrally and peripherally acting 5HT(1B)/(1D) agonist for migraine. Cephalalgia 1997;17(S18):4–14
   PubMedGoogle Scholar
• Martin GR, Robertson AD, MacLennan SJ, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 1997;121: 157–64
   PubMed Web of Science ®Google Scholar
• Palmer KJ, Spencer CM. Zolmitriptan. CNS Drugs 1997; 7:468–78
   Web of Science ®Google Scholar
• Seaber E, On N, Phillips S, et al. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol 1996;41: 141–7
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Dixon R, Lassen LH, et al. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 1996;16: 270–5
   Google Scholar
• Seaber E, On N, Dixon RM, et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 1997;43: 579–87
   PubMed Web of Science ®Google Scholar
• Seaber EJ, Peck RW, Smith DA, et al. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br J Clin Pharmacol 1998;46:433–9
   PubMed Web of Science ®Google Scholar
• Jhee SS, Salazar DE, Ford NF, et al. Monitoring of acute migraine attacks: placebo response and safety data. Headache 1998;38: 35–8
   Google Scholar
• Visser WH, Klein KB, Cox RC, et al. 311C90, a new central and peripherally acting 5HT-1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled dose-range finding study. Neurology 1996; 46:522–26
   PubMed Web of Science ®Google Scholar
• Dahlof C, Diener HC, Goadsby PJ, et al. Zolmitriptan, a 5HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol 1998;5: 535–43
   Google Scholar
• Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology 1997;49: 1210–18
   PubMed Web of Science ®Google Scholar
• Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997;49: 1219–25
   PubMed Web of Science ®Google Scholar
• Ryan RE, Diamond S, Giammarco RAM, et al. Efficacy of zolmitriptan at early time points for acute treatment of migraine and treatment of recurrence. CNS Drugs 2000; 13:215–26
   Web of Science ®Google Scholar
• Terzoudi M, Kavvadia E, Tagaris GA, et al. A comparative study of the effectiveness of sumatriptan, zolmitriptan and acetylsalicylic lysine in migraine attacks, in the emergency room. Cephalalgia 1999;19:362
   Web of Science ®Google Scholar
• The Oral Sumatriptan and Aspirin plus Metaclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus metaclopramide in the acute treatment of migraine. Eur Neurol 1992;32:177–84
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared to oral sumatriptan for migraine. Lancet 1995;346:923–6
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs step care strategies for migraine. The Disability in Strategies of Care (DISC) Study: a randomized trial. J Am Med Assoc 2000;284: 2599–605
   Google Scholar
• Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999;53:988–94
   PubMed Web of Science ®Google Scholar
• Geraud G, Olesen J, Pffafenrath V, et al. Comparison of the efficacy and of zolmitriptan and sumatriptan: issues migraine trial design. Cephalalgia 2000;20: 30–8
   Google Scholar
• Gallagher RM, Dennish G, Spierings EGLH, Chitra R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache 2000;40:119–28
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Boes-Hansen S, Farkkila AM. Zolmitriptan nasal spray is fast-acting and highly effective in the acute treatment of migraine. Eur J Neurol 2000;7(Suppl 3):82
   Google Scholar
• Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine. Neurology 1997;49:1225–30
   PubMed Web of Science ®Google Scholar
• Dahlof C. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Cephalalgia 1999;19:769–78
   PubMed Web of Science ®Google Scholar
• Diamond S, Eklind A, Jackson T. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Family Med 1998;7:234–40
   PubMedGoogle Scholar
• Ashford E, Salonen R, Saiers J, Woessner M. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia 1998;18:273–7
   PubMed Web of Science ®Google Scholar
• Bahra A, Gawel MJ, Hardebo J-E, et al. Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology 2000;54:1832–9
   PubMed Web of Science ®Google Scholar
• Monstad I, Krabbe A, Micieli G, et al. Preemptive oral treatment with sumatriptan during a cluster period. Headache 1995;35:607–13
   PubMed Web of Science ®Google Scholar
• Schuh-Hofer S, Kinze S, Einhaupl KM, Arnold G. Treatment of acute cluster headache with 20 mg sumatriptan nasal spray: an open pilot study. Cephalalgia 2000;20: 330
   Google Scholar
• Hardebo JE, Dahlof C. Sumatriptan nasal spray (20 mg/dose) in the acute treatment of cluster headache. Cephalalgia 1998;18:487–9
   PubMed Web of Science ®Google Scholar
• Fox A. Comparative tolerability of oral 5-HT1B/1D agonists. Headache 2000;40:521–7
   PubMed Web of Science ®Google Scholar
• Ferrari M. Which oral triptan to chose? In: Diener H-C, ed. Drug Treatment of Migraine and Other Headaches. Monographs in Clinical Neuroscience Series. Basel: Karger, 2000: 216–21
   Google Scholar
• Humphrey PPA, Feniuk W, Marriott AS, et al. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 1991;31:282–90
   PubMed Web of Science ®Google Scholar
• Adham N, Kao H-T, Schechter LE, et al. Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci 1993;90: 408–12
   PubMed Web of Science ®Google Scholar
• Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. Br J Pharmacol 1989;96: 83–90
   Google Scholar
• Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990;99:202–6
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in man and cat. Ann Neurol 1993;33:48–56
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994; 34:394–9
   PubMed Web of Science ®Google Scholar
• Kaube H, Hoskin KL, Goadsby PJ. Sumatriptan inhibits central trigeminal neurons only after blood–brain barrier disruption. Br J Pharmacol 1993;109:788–92
   PubMed Web of Science ®Google Scholar
• Shepheard SL, Williamson DJ, Williams J, et al. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacology 1995;34: 255–61
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)-1-D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain 1996;67:355–9
   PubMed Web of Science ®Google Scholar
• Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31:291–4
   PubMed Web of Science ®Google Scholar
• Rance D, Clear N, Dallman L, et al. Physicochemical comparison of eletriptan and other 5-HT1D-like agonists as a predictor of oral absorption potential. Headache 1997;37: 328
   Google Scholar